J&J | Built to matter: oncology startup strategies to stand out in a crowded marke
Johnson & Johnson invites oncology innovators and ecosystem partners to explore what it takes to stand out in today's increasingly competitive innovation landscape. As capital, strategic attention and acquisition interest become more concentrated, emerging companies need more than scientific novelty alone. They also need a focused strategy, a credible development path and a clear understanding of where they can create value
6 October 2026, 15:00 – 18:00 CET, Utrecht (NL) & virtual
Johnson & Johnson invites oncology innovators and ecosystem partners to explore what it takes to stand out in today's increasingly competitive innovation landscape. As capital, strategic attention and acquisition interest become more concentrated, emerging companies need more than scientific novelty alone. They also need a focused strategy, a credible development path and a clear understanding of where they can create value.
“Built to matter” will bring together investors, pharma leaders, biotech executives and advisors to discuss how oncology startups can position themselves for investment, partnership and potential acquisition. Topics will include evolving expectations around competitive positioning and the strategic decisions that can shape a company's future options.
Join the discussion in the Netherlands or virtually to hear perspectives from across the oncology innovation ecosystem. Startups, academic innovators, investors, technology transfer offices, incubators and ecosystem partners are welcome to register.
Source: Johnsen & Johnsen
